Drug intelligence / Profile preview

ITI-8000

Development stage: Preclinical
Lead developer: Immunomic Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ITI-8000 is a monoclonal antibody developed as a next-generation checkpoint inhibitor targeting the activin A receptor type 1C (ALK7). By inhibiting ALK7, also known as activin A receptor type 1C, ITI-8000 blocks the binding of activin A, which is implicated in tumor growth and immune evasion. The drug is being investigated primarily for neoplasms (cancers) and remains in preclinical development. It was originated and is actively developed by Immunomic Therapeutics[1][2].

Targets

ACVR1C (Activin A Receptor Type 1C)

Beyond the preview

Go deeper on ITI-8000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITI-8000.

Explore the full profile